The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
New Grünenthal CEO effective October 1, 2016
Grünenthal appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer
Grünenthal Group announced that its Supervisory Board has named Gabriel Baertschi to become Grünenthal’s new CEO as of October 1, 2016.
Gabriel Baertschi will join Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where he currently serves as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques, who has been the CEO of the Grünenthal Group.